125 related articles for article (PubMed ID: 12853891)
21. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
23. [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
Kouchi Y; Maeda Y; Morinaga H; Ohuchida A
J Toxicol Sci; 1996 Nov; 21 Suppl 3():691-701. PubMed ID: 9021669
[TBL] [Abstract][Full Text] [Related]
24. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
[TBL] [Abstract][Full Text] [Related]
25. [Three successful case reports of advanced gastric cancer with chemotherapy].
Yamamoto M; Niinobu T; Taniguchi H; Kotobuki T; Fukunaga K; Kawai M
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1689-92. PubMed ID: 15553684
[TBL] [Abstract][Full Text] [Related]
26. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Tanaka T; Fujita S; Tanaka N; Ooka M; Okajima S; Tanaka N
Gan To Kagaku Ryoho; 2005 Jun; 32(6):841-5. PubMed ID: 15984528
[TBL] [Abstract][Full Text] [Related]
27. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
28. [Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer].
Yonemura Y; Endou Y; Tochiori S; Bando E; Kawamura T; Shimada T; Miyamoto K; Tanaka M; Sasaki T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1635-9. PubMed ID: 16315893
[TBL] [Abstract][Full Text] [Related]
29. [A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer].
Kamata T; Hayashi Y; Minatoya G; Michiwa Y; Onishi I; Takeda T; Koyasaki N; Kanno M
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1419-22. PubMed ID: 11681250
[TBL] [Abstract][Full Text] [Related]
30. Continuous infusion of 5-fluorouracil plus low-dose cisplatin in tumor-bearing mice.
Kamano T; Mikami Y; Shirasaka T
Anticancer Drugs; 1997 Jul; 8(6):632-6. PubMed ID: 9300579
[TBL] [Abstract][Full Text] [Related]
31. [Effect of cepharanthine on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207)--5-fluorouracil delivery into tumor tissue].
Ono M
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1379-92. PubMed ID: 2509603
[TBL] [Abstract][Full Text] [Related]
32. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
[TBL] [Abstract][Full Text] [Related]
33. [Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization].
Tasaka K; Okada Y; Tomofuji Y; Chinzei T
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1631-5. PubMed ID: 12355951
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
35. [Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
Nakata B; Hirakawa K
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1962-8. PubMed ID: 15570921
[TBL] [Abstract][Full Text] [Related]
36. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats.
Fujii S; Shimamoto Y; Ohshimo H; Imaoka T; Motoyama M; Fukushima M; Shirasaka T
Jpn J Cancer Res; 1989 Feb; 80(2):167-72. PubMed ID: 2498251
[TBL] [Abstract][Full Text] [Related]
37. Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo.
Araki H; Fukushima M; Kamiyama Y; Shirasaka T
Cancer Lett; 2000 Nov; 160(2):185-91. PubMed ID: 11053648
[TBL] [Abstract][Full Text] [Related]
38. [Combination therapy with TS-1].
Fujii M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2040-5. PubMed ID: 16352926
[TBL] [Abstract][Full Text] [Related]
39. [An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study].
Hayashi T; Yamaguchi S; Kito S; Tanaka G; Kurokawa K; Hirota T
J Toxicol Sci; 1996 Nov; 21 Suppl 3():527-44. PubMed ID: 9021660
[TBL] [Abstract][Full Text] [Related]
40. [Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Yang JL; Jiao SC; Dai GH; Li F; Zhao H; Li Y; Xu JM; Liu W; Zhang Y; Niu RG; Xie XD; Song SP; Zhang FC; Lu HS; Wang J
Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1412-4. PubMed ID: 18953882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
